

## Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

J. Franklin<sup>1\*</sup>, A. Pluetschow<sup>1</sup>, M. Paus<sup>1</sup>, L. Specht<sup>2</sup>, A.-P. Anselmo<sup>3</sup>, A. Aviles<sup>4</sup>, G. Biti<sup>5</sup>, T. Bogatyreva<sup>6</sup>, G. Bonadonna<sup>7</sup>, C. Brillant<sup>1</sup>, E. Cavalieri<sup>3</sup>, V. Diehl<sup>1</sup>, H. Eghball<sup>8</sup>, C. Fermé<sup>9</sup>, M. Henry-Amar<sup>10</sup>, R. Hoppe<sup>11</sup>, S. Howard<sup>12</sup>, R. Meyer<sup>13</sup>, D. Niedzwiecki<sup>14</sup>, S. Pavlovsky<sup>15</sup>, J. Radford<sup>16</sup>, J. Raemaekers<sup>17</sup>, D. Ryder<sup>16</sup>, P. Schiller<sup>1</sup>, S. Shakhtarina<sup>6</sup>, P. Valagussa<sup>7</sup>, J. Wilimas<sup>12</sup> & J. Yahalom<sup>18</sup>

<sup>1</sup>German Hodgkin Study Group, University of Cologne, Germany; <sup>2</sup>Rigshospitalet, Copenhagen, Denmark; <sup>3</sup>University of La Sapienza, Rome, Italy; <sup>4</sup>Oncology Hospital, National Medical Center, Mexico City, Mexico; <sup>5</sup>University of Florence, Florence, Italy; <sup>6</sup>Medical Radiological Research Centre, Obninsk, Russia; <sup>7</sup>Istituto Nazionale Tumore, Milan, Italy; <sup>8</sup>Institut Bergonie, Bordeaux; <sup>9</sup>Hopital Saint-Louis, Paris; <sup>10</sup>Centre Regional Francoise Baclesse, Caen, France; <sup>11</sup>Stanford University School of Medicine, Stanford, CA; <sup>12</sup>St Jude's Children's Research Hospital, Memphis, TN, USA; <sup>13</sup>Hamilton Regional Cancer Center, Ontario, Canada; <sup>14</sup>Duke University School of Medicine, Durham, NC, USA; <sup>15</sup>FUNDALU, Buenos Aires, Argentina; <sup>16</sup>Christie Hospital, Manchester, UK; <sup>17</sup>University Medical Center Nijmegen, Nijmegen, The Netherlands; <sup>18</sup>Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Received 20 March 2006; revised 3 July 2006; accepted 11 July 2006

**Background:** Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial.

**Patients and Methods:** We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto's method.

**Results:** Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62–0.98 and  $P = 0.03$ ). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00–1.89 and  $P = 0.05$ ). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR ( $P = 0.28$ ) although more breast cancers occurred with EF-RT ( $P = 0.04$  and OR = 3.25).

**Conclusions:** Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies.

**Key words:** chemotherapy, Hodgkin's lymphoma, meta-analysis, radiotherapy, second malignancies

### introduction

Hodgkin's lymphoma (HL) occurs predominantly in young adults and is one of the most curable malignancies. With current treatment approaches, most patients achieve a lasting complete remission, but secondary malignancies (SM) remain a serious late effect of treatment [1].

Evidence concerning the influence of treatment modality on SM risk is provided by numerous retrospective cohort studies based on large, often pooled datasets [2–22], as well as case–

control studies [23–30]. Results, especially concerning solid tumours (ST), vary considerably. In most reports, the analysed treatment categories are based on both first-line and salvage modalities. Some, e.g. Boivin et al. [26], used time-dependent covariates to allow for the effects of later treatments. A few studies, such as Biti et al. [9], evaluated only initial treatment, but censored patients at relapse. Thus, such reports do not enable the 'overall' SM risks (i.e. due to both first-line and possible salvage therapy) associated with first-line treatment strategies to be compared directly. Only the analyses by Dores et al. [20] and Ng et al. [21] investigated the effect of initial treatment strategy on overall SM risk.

\*Correspondence to: Dr J. Franklin, German Hodgkin Study Group, Herder Strasse 52–54, 50931 Koeln, Germany. Tel: +49-21-478-5894; Fax: +49-221-478-6311; E-mail: jeremy.franklin@uk-koeln.de

The main objective of the present investigation was to compare overall SM risks in HL patients following first-line treatment with radiotherapy alone (RT), chemotherapy alone (CT) or combined chemoradiotherapy (CRT). Involved-field (IF) and extended-field (EF) RT were also compared. The investigation was carried out and electronically published as a Cochrane Collaboration systematic review [31].

## methods

We aimed to collect individual patient data (IPD) from all randomised trials comparing RT, CT and/or CRT or comparing IF with EF or subtotal or total nodal RT (with or without CT) in newly diagnosed HL patients which enrolled at least 30 patients and which finished recruitment before or during 2000. Trials were sought in electronic literature databases, relevant conference proceedings from 1980 to 2001, lists of clinical trials, reference lists of all relevant retrieved publications and previous meta-analyses of HL.

IPD were requested from investigators from each eligible trial, including date of birth, sex, date of (first) HL diagnosis, stage of disease, presence or absence of B symptoms, treatment arm by randomisation, date of randomisation, remission status at the end of first-line treatment (with date), occurrence and date of relapse, occurrence, date and type of SM, occurrence and date of death and date of last follow-up information. All data were checked for completeness and consistency.

All patients who were randomly assigned in each trial were included (intention-to-treat), unless the first diagnosis of HL was reported as erroneous. A small number of patients for whom the relevant data fields were missing had to be excluded. As a preparatory step, each trial was analysed separately, comparing the treatment arms with respect to recruitment times, patient characteristics, complete remission rate, length of follow-up, overall survival (OS), event-free survival and time to SM. This step investigates the comparability of the treatment arms and the consistency of the data with previous publications of the trial.

Each trial was assessed for the following aspects of trial quality: randomisation method, adherence to the intention-to-treat principle, reliability of SM follow-up methods, completeness of follow-up and completeness of SM reporting. To assess completeness of follow-up, the median follow-up time was calculated using the Kaplan–Meier method [32]. The distribution of last information dates was quantified; both high variability (large interquartile range) in relation to the median follow-up time and significant differences between treatment arms indicate less reliable follow-up.

Furthermore, observed SM incidence was compared with that expected in an age- and sex-matched cohort from the general population using data from USA and European cancer registries.

Randomised comparisons of RT versus CRT, CT versus CRT, RT versus CT and IF-RT versus EF-RT (with or without CT), respectively, were combined across the appropriate trials as follows. First, a measure of the ratio of SM incidence between the treatment arms of each trial was calculated separately, together with an estimate of the variance of this quantity, according to the method of Peto et al. [33, 34]. This method makes comparisons within each time period separately and thus takes account of the varying lengths of follow-up among the various trials. These measures were combined across trials relevant to the comparison being made to obtain a pooled Peto odds ratio (OR) for SM rate, i.e. the estimated SM treatment effect. For the OR, 95% confidence intervals (CIs) are also given. The three classes of SM [acute leukaemia (AL), non-Hodgkin's lymphoma (NHL) and ST] were also analysed separately, censoring at occurrence of the other two classes, as were lung and breast ST.

Subgroup analyses were performed to investigate whether the SM treatment effect depended upon patient characteristics or treatment type.

The following subgroups were employed: stage (Ann Arbor) (early stage = I and II and advanced stage = III and IV), age (0–15 years, 16–39 years, 40–59 years and 60 years and older) and sex. Treatment-related subgroups were extent of RT (IF, more than IF) for CT versus CRT, type of CT (anthracycline containing, others) for RT versus CRT and CT versus CRT. Results are displayed chronologically by recruitment period in order to reveal any time period effects.

Separate analyses were conducted with and without including SM that occurred after salvage therapy. For the latter, follow-up times were censored at HL progression/relapse and subsequent SM were ignored.

Sensitivity analyses were performed to check that the results were not crucially dependent on selection criteria or analysis methods. First, analyses were repeated with the exclusion of the less complete follow-up periods in each trial: for each trial, follow-up times were censored at the calendar date at which 75% of surviving patients in that trial were still being followed ('cut-off'). Secondly, SM risk comparisons were analysed together by Cox proportional hazards regression [35] including relevant covariates and stratified by trial. Thirdly, the analysis was rerun excluding confounded trials. Fourthly, SM and ST analyses were repeated excluding non-melanoma skin cancers (NMSC) (as in many previous investigations of SM; some included trials did not record such cancers). Finally, the cumulative incidence method [36, 37], which allows for competing risks (deaths from other causes compete with second malignancies), was employed and the results qualitatively compared with those of the main analysis.

## results

Seventy-six trials were identified as eligible, of which one was excluded after correspondence with the authors because it was not randomised. Although trials with <30 patients were to be excluded, we included a number of small Stanford University trials by amalgamating those with similar design and simultaneous or successive recruitment, and counted and analysed these as a single 'trial.' One dataset (St Jude Children's Research Hospital) received as a single trial was split into two trials for the analysis, each with <30 patients, since two distinct study designs were applied to two groups defined by stage. One submitted dataset was excluded because no second malignancies were recorded.

In total, IPD from 37 trials could be analysed [38–71], including four which contributed to more than one treatment comparison. The earliest trial began accrual in 1962 and the latest ended accrual in 2000. Trial size ranged from 24 to 1136 patients. Data could not be obtained for a large number of otherwise eligible studies [72–103] as noted in Tables 1–4.

The analysed dataset included 9312 patients and 705 cases of SM: 92 AL, 103 NHL, 494 ST and 16 unspecified. The most common sites of ST were lung (97), skin (87: melanoma 19, non-melanoma 57 and unspecified 11), female breast (65), small intestine/colon/rectum (33) and stomach (20). Median OS times following occurrence of SM were as follows: AL 7 months, NHL 34 months and ST 36 months.

### RT versus CRT

In total, 15 studies with 3343 patients (68% of those in all the eligible identified trials for this comparison), recruited from 1966 to 1998, were included (Table 1). IPD could not be obtained for 12 other trials. Most trials were for stage I–II patients only, while three trials also enrolled stage III patients.

**Table 1.** Trials analysed for the comparison RT versus CRT<sup>a</sup>

Trial	Recruitment period/median follow-up (years)	Stage and other criteria	No. of patients in dataset	RT	CRT	References
Stanford H2-H6, K1, R1	1968–1979, 27	I–IV	269	EF/TNI	6MOPP + EF/TNI	
LYGRA II	1971–1985, 25	I–II	326	(S)TNI	6MOPP + mantle	[53]
St Jude IIB	1972–1975, 27	IIA, IIIA	24	EF	VCP + EF	[67]
Manchester HD1	1974–1981, 24	I–II	115	EF	MVPP + EF	[54]
Stanford S1	1974–1980, 22	IA, IIA	71	EF	6MOP(P) + IF	
EORTC H5U	1977–1982, 13	I–II	296	(S)TNI	6MOPP + mantle	[41]
Stanford C1–C3, G1	1980–1985, 12	I, II, IIIA	106	(S)TNI	6VBM + IF	[68]
Mexico 82HO31	1983–1988, 16	I–II	208	Mantle	6ABVD + mantle	[57]
Rome RT versus CRT	1983–1993, 11	IIA	103	STNI	ABVD + STNI	[66]
EORTC H7F	1988–1993, 9	I–II	333	STNI	6EBVP + IF	[42]
Manchester VAPEC-B	1989–1997, 8	IA, IIA	124	IF	VAPEC-B + IF	[56]
EORTC-GELA H8F	1993–1998, 6	I–II	543	STNI	6MOPP/ABV + IF	[43]
GHSG HD7	1994–1998, 5	I–II	627	EF	2ABVD + EF	[49]
CALGB 6604	1966–1971, 27	III	40	TNI	Mechlorethamine + vinblastine + IF/TNI	[38]
CALGB 7451	1974–1981, 17	III	168	TNI	6BOPP + TNI	[39]

<sup>a</sup>Excluded trials (eligible, but individual patient data not obtained): BNLI TNI versus LOPP + TNI ( $n = 85$ ), Chicago EF versus COPP + EF ( $n = 49$ ), Eastern Cooperative Oncology Group 2475 EF versus C/MOPP + IF ( $n = 34$ ), GEMH H9-69 RT versus MOPP + RT ( $n = 198$ ), IHDCS (Pediatric Oncology Group) IF/EF versus MOPP + IF ( $n = 220$ ), Lyon LMS80a EF versus 6MOPP + IF ( $n = 48$ ), Moscow EF versus CVPP + EF/IF ( $n = 95$ ), NCI EF versus MOPP + EF ( $n = 87$ ), Roswell Park IF/TNI versus ChIVPP + IF/TNI ( $n = 165$ ), SWOG 781 EF versus 6MOPP + IF ( $n = 235$ ), SWOG 9133 STNI versus 3(doxorubicin + vinblastine) + STNI ( $n = 348$ ), Western CSG 135 TNI versus MOPP + TNI ( $n = 40$ ).

ABVD, doxorubicin bleomycin vinblastine dacarbazine; BOPP, BCNU vincristine procarbazine prednisone; CALGB, Cancer and Leukaemia Group B; CRT, combined chemoradiotherapy; CVPP, cyclophosphamide vinblastine procarbazine prednisone; EF, extended field; EBVP, epirubicin bleomycin vinblastine prednisone; EORTC, European Organisation for Research and Treatment of Cancer; GELA, Groupe d'Etudes des Lymphomes de l'Adulte; GHSG, German Hodgkin Study Group; IF, involved field; MOPP, combination chemotherapy with mechlorethamine, vincristine, procarbazine and prednisone; MVPP, mechlorethamine vinblastine procarbazine prednisone; RT, radiotherapy alone; (S)TNI, (sub)total nodal irradiation; VAPEC-B, doxorubicin cyclophosphamide etoposide vincristine bleomycin prednisone; VBM, vinblastine bleomycin methotrexate; VCP, vincristine cyclophosphamide procarbazine.

Eight trials had an unconfounded design, i.e. the same radiotherapy was planned in each treatment arm. Seven trials were confounded, with (sub)total nodal irradiation [(S)TNI] in the RT arm and IF or mantle field in the CRT arm. The nine earlier trials used a regimen without anthracycline [a combination chemotherapy with mechlorethamine, vincristine, procarbazine and prednisone (MOPP) typically six times], whereas the six more recent trials included an anthracycline doxorubicin bleomycin vinblastine dacarbazine (ABVD) typically six times.

There was a higher overall risk of SM with RT alone compared with CRT ( $P = 0.03$ , OR = 0.78 for all stages together)—see Figure 1. This effect was most marked in stage III patients ( $P = 0.02$ , OR = 0.45) and did not reach significance in patients with stage I/II disease ( $P = 0.13$ , OR = 0.83).

The treatment effect of higher SM risk with RT alone was also seen when considering ST only ( $P = 0.05$ , OR = 0.78) and when considering NHL only ( $P = 0.03$ , OR = 0.46). AL risk was higher (though not significantly so) with CRT ( $P = 0.21$ , OR = 1.55 for early stages). No treatment effects were seen when considering either lung cancer or breast cancer alone.

If follow-up was censored at progression/relapse of HL, the SM treatment effect largely disappeared in both early and advanced stages ( $P = 0.51$ , OR = 1.11 for all stages together). Similar results were seen when considering ST only or NHL only; whereas, for AL only, there was a significantly higher risk

with CRT ( $P = 0.01$ , OR = 3.40) when censoring at progression/relapse.

### CT versus CRT

Sixteen studies with 2861 patients in total (53% of those in all the eligible identified trials), recruited from 1966 to 2000, were included (Table 2). Data could not be obtained for 12 other trials. There were 696 patients with early-stage (I–II) and 2165 with advanced-stage (III–IV) disease.

Ten trials were unconfounded, i.e. identical chemotherapy in each treatment arm, typically six cycles of MOPP or ABVD. Only the four most recent trials included an anthracycline (doxorubicin). Three trials were partially and three fully confounded, specifying more cycles in the CT arm than the CRT arm for some and all cases, respectively. The earliest five trials (1966–1974) used EF-RT or TNI, whereas the majority of subsequent trials used IF-RT.

SM risk was higher with CRT than with CT alone ( $P = 0.05$ , OR = 1.38 for all stages together)—see Figure 2. In early stages alone, no significant effect ( $P = 0.73$ , OR = 1.17) was seen.

A modest treatment effect was seen in AL alone for all stages together ( $P = 0.07$ , OR = 1.82). There was no treatment effect for NHL or ST alone.

The effects are largely unchanged, but favour CT somewhat more strongly, if follow-up is censored at progression/relapse

**Table 2.** Trials analysed for the comparison CT versus CRT<sup>a</sup>

Trial	Recruitment period/median follow-up (years)	Stage and other criteria	No. of patients in dataset	CT	CRT	References
CALGB 7751	1977–1983, 12	I–II	61	6CVPP	6CVPP + IF	[39]
GATLA 9-H-77	1977–1986, 9	I–IV	473	6CVPP	6CVPP + IF	[45, 46]
Mexico 82HO31	1983–1988, 16	I–II	201	6ABVD	6ABVD + mantle	[57]
MSKCC 90-44	1990–2000, 6	I–IIIA	152	6ABVD	6ABVD + IF/EF	[59, 60]
CALGB 6604	1966–1971, 27	III	67	Mechlorethamine + vinblastine	Mechlorethamine + vinblastine + TNI	[38]
Stanford K7, S8	1969–1980, 22	IV	58	6MOPP	6MOPP + TNI	
NCIC HD1	1972–1976, 11	IIIB–IV	111	6/10MOPP	6MOPP + EF	[61]
St Jude IIC	1972–1975, 27	IIB, IIIB, IV	24	VCP	VCP + EF	[67]
CALGB 7451	1974–1981, 17	III	178	6BOPP	6BOPP + TNI	[39]
Obninsk, advanced	1974–1981, 17	II–IV	284	6/12COPP	6COPP + IF/EF	[62]
CALGB 7551	1975–1982, 14	IIIB–IV	337	6/12CVPP	6CVPP + IF	[39]
Manchester HD2	1975–1984, 21	IIIA	65	6MVPP	6MVPP + IF	[55]
Stanford C7–10, C12–15	1980–1987, 14	III–IV	74	6(MOPP or PAVe) + ABVD	6PAVe + TNI	
GHSg HD3 <sup>b</sup>	1982–1988, 14	IIIB–IV	100	4(COPP + ABVD)	3(COPP + ABVD) + IF	[48]
EORTC 20884 <sup>b</sup>	1989–2000, 6	III–IV	333	6/8MOPP/ABV	6/8MOPP/ABV + IF	[40]
GELA H89	1989–1996, 6	IIIB–IV	419	8(MOPP/ABV or ABVPP)	6(MOPP/ABV or ABVPP) + (S)TNI	[47]

<sup>a</sup>Excluded trials (eligible, but individual patient data not obtained): CCG 521 6MOPP/ABVD versus 6ABVD + IF ( $n = 111$ ), CCG 5942 COPP/ABV versus COPP/ABV + IF ( $n = 501$ ), ECOG EST1476 6Bleo-MOPP + 3ABVD versus 6Bleo-MOPP + IF ( $n = 232$ ), ECOG EST1481 (BCVPP or MOPP/ABVD) versus BCVPP + IF ( $n = 319$ ), Lyon LMS80b 12MOPP/CVPP versus 6MOPP + EF ( $n = 58$ ), Mexico Ho8326 6EBVD versus 6EBVD + IF ( $n = 118$ ), NCI 6MOPP versus 6MOPP + EF ( $n = 36$ ), POG 8625 3MOPP/ABVD versus 2MOPP/ABVD + IF ( $n = 247$ ), POG 8725 4MOPP/ABVD versus 4MOPP/ABVD + TNI ( $n = 181$ ), SWOG 7518 10MOPP-Bleo versus 3MOPP-Bleo + TNI ( $n = 118$ ), SWOG 774/775 MOPP(MOPP/Bleo) versus MOPP(MOPP/Bleo) + IF ( $n = 254$ ), SWOG 7808 6MOPP-BAP versus 6MOPP-BAP + IF ( $n = 278$ ).

<sup>b</sup>Randomisation only if complete remission after chemotherapy.

ABV, doxorubicin bleomycin vinblastine; ABVD, doxorubicin bleomycin vinblastine dacarbazine; ABVPP, doxorubicin bleomycin vinblastine procarbazine prednisone; BOPP, BCNU vincristine procarbazine prednisone; CALGB, Cancer and Leukaemia Group B; COPP, cyclophosphamide vincristine procarbazine prednisone; CRT, combined chemoradiotherapy; CT, chemotherapy alone; CVPP, cyclophosphamide vinblastine procarbazine prednisone; ECOG, Eastern Cooperative Oncology Group; EF, extended field; EORTC, European Organisation for Research and Treatment of Cancer; GATLA, Grupo Argentino de Tratamiento de la Leucemia Aguda; GELA, Groupe d'Etudes des Lymphomes de l'Adulte; GHSg, German Hodgkin Study Group; IF, involved field; MOPP, combination chemotherapy with mechlorethamine, vincristine, procarbazine and prednisone; MSKCC, Memorial Sloan-Kettering Cancer Center; MVPP, mechlorethamine vinblastine procarbazine prednisone; PAVe, procarbazine melphalan vinblastine; POG, Pediatric Oncology Group; (S)TNI, (sub)total nodal irradiation; VCP, vincristine cyclophosphamide procarbazine.

**Table 3.** Trials analysed for the comparison RT versus CT<sup>a</sup>

Trial	Recruitment period/median follow-up (years)	Stage and other criteria	No. of patients in dataset	RT	CT	References
Rome, Florence	1979–1982, 16	IA, IIA	94	EF	6MOPP	[64]
Mexico 82HO31	1983–1988, 16	I–II	205	Mantle	6ABVD	[57]
CALGB 7451	1974–1981, 17	III	116	TNI	6BOPP	[39]

<sup>a</sup>Excluded trials (eligible, but individual patient data not obtained): BNLI TNI versus 6MOPP ( $n = 165$ ), NCI EF versus 6MOPP ( $n = 86$ ), St Bartholomews, London, TNI versus 6MVPP ( $n = 60$ ).

ABVD, doxorubicin bleomycin vinblastine dacarbazine; BOPP, BCNU vincristine procarbazine prednisone; CALGB, Cancer and Leukaemia Group B; CT, chemotherapy alone; EF, extended field; MOPP, combination chemotherapy with mechlorethamine, vincristine, procarbazine and prednisone; RT, radiotherapy alone; TNI, total nodal irradiation.

( $P = 0.01$ , OR = 1.60 for all stages together, no difference for early stages alone). In this case, there are somewhat more ST ( $P = 0.07$ , OR = 1.60) and significantly more leukaemias ( $P = 0.01$ , OR = 2.75) with CRT than with CT (but no difference in NHL).

### RT versus CT

Three studies with 415 patients in total (57% of those in eligible identified trials), recruited from 1974 to 1988, were included (Table 3). IPD could not be obtained for three other trials. Two trials recruited stages I–II and one recruited stage III. Mantle

**Table 4.** Trials analysed for the comparison IF-RT versus EF-RT<sup>a</sup>

Trial	Recruitment period/median follow-up (years)	Stage and other criteria	No. of patients in dataset	IF-RT	EF-RT	References
Stanford H1, L1-L2	1962–1970, 32	I–III	209	IF	EF	
Lygra I	1969–1971, 32	I–II	50	IF	EF	[52]
GPMC <sup>b</sup>	1976–1981, 22	I–II, IIIA	90 of 335 <sup>c</sup>	3/6MOPP + IF, sandwich	3/6MOPP + EF, sandwich	[51]
Obninsk R18	1977–1983, 17	I–II	237	6COPP + IF	3/6COPP + EF	[63]
Milan 9005	1990–1996, 8	I, IIA	140	4ABVD + IF	4ABVD + STNI	[58]
EORTC H8U	1993–1999, 6	I–II	996	4/6MOPP/ABV + IF	4MOPP/ABV + EF	[44]
GHSG HD8	1993–1998, 4	I–II, IIIA	1136	2(COPP + ABVD) + IF	2(COPP + ABVD) + EF	[50]
Rome HD94 <sup>d</sup>	1993–1995, 7	II, IIIA	130 of 209 <sup>c</sup>	4ABVD + IF	4ABVD + STNI	[65]
CALGB 6604	1966–1971, 27	III	45	Vinblastine + mechlorethamine + IF	Vinblastine + mechlorethamine + EF	[38]
Obninsk advanced	1974–1981, 17	II–IV	200	6COPP + IF	6COPP + EF	[62]

<sup>a</sup>Excluded trials (eligible, but individual patient data not obtained): BNLI IF versus EF ( $n = 603$ ), Can-AM RHDG IF versus EF ( $n = 460$ ), GEMH H7701 CT + IF versus CT + EF ( $n = 79$ ).

<sup>b</sup>Randomisation after 3MOPP.

<sup>c</sup>Data from some participating centres not received.

<sup>d</sup>Randomisation only if complete or partial remission after chemotherapy.

ABV, doxorubicin bleomycin vinblastine; ABVD, doxorubicin bleomycin vinblastine dacarbazine; CALGB, Cancer and Leukaemia Group B; COPP, cyclophosphamide vincristine procarbazine prednisone; EF, extended-field; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; GPMC, Groupe Pierre et Marie Curie; IF, involved field; MOPP, combination chemotherapy with mechlorethamine, vincristine, procarbazine and prednisone; RT, radiotherapy alone; STNI, subtotal nodal irradiation.

field, EF and TNI radiotherapy were compared with six cycles of MOPP, BCNU, vincristine, procarbazine and prednisone (BOPP) and ABVD, respectively.

There were non-significantly more SM with CT than RT ( $P = 0.13$ , OR = 2.12 for all stages); this difference was more pronounced for the early stages ( $P = 0.05$ , OR = 3.37)—see Figure 3. There were insufficient events to analyse each type of SM. In the analysis censoring follow-up at progression and relapse, no significant treatment effect was seen ( $P = 0.30$ , OR = 1.99).

### IF-RT versus EF-RT

Ten studies with 3221 patients in total (69% of those in eligible identified trials), recruited from 1962 to 1999, were included (Table 4). IPD could not be obtained for three other trials. Eight trials were mainly for early- and two mainly for advanced-stage disease.

Two studies (259 patients in total) planned no chemotherapy, six planned identical chemotherapy in each arm and two specified, in certain cases, more cycles in the IF-RT arm than in the EF-RT arm (i.e. partially confounded). Chemotherapy was MOPP like, MOPP/ABVD like or ABVD except in one study, usually with three to six cycles.

Neither were there significant differences in the rate of SM between EF-RT and IF-RT ( $P = 0.28$ , OR = 1.17 for all stages)—see Figure 4—nor were there significant differences in AL, NHL or ST rates. For breast cancers alone, there was a significantly greater risk with EF-RT ( $P = 0.04$ , OR = 3.25) but no significant difference for lung cancers ( $P = 0.22$ ).

When follow-up was censored at progression/relapse, the tendency to more SM with EF-RT was stronger but still not significant ( $P = 0.09$ , OR = 1.54).

For all comparisons, subgroup analyses did not reveal relevant differences in the SM OR between subgroups. No time trends are discernable in the Forest plots arranged in chronological order of recruitment period (Figures 1–4). Sensitivity analyses did not lead to relevant changes in the results, although restrictions to unconfounded trials, to fully documented time periods or exclusion of NMSC led to reduced significance of any treatment effects. Competing risk analyses produced results in qualitative agreement with the main analysis.

### discussion



This systematic review is one of the largest investigations of SM yet performed. To the authors' knowledge, it is the only large study of SM risk employing randomised comparisons, except for the meta-analyses by Loeffler et al. [104] and (concerning deaths from SM) Specht et al. [77].

### conclusions

RT as a first-line treatment strategy for stage I–III patients leads to a higher overall rate of all SM, ST and NHL, respectively, than a combined modality strategy. This appears to be due to the significantly greater rate of progression/relapse and therefore intensive salvage therapy after RT alone, since the effect vanishes in an analysis censored at progression/relapse.

Administration of RT in addition to CT in first-line treatment of advanced-stage patients appears to increase the overall rate of all SM and AL, respectively (borderline significance). There was no evidence of such an effect in early stages, but data were limited.

Perhaps surprisingly, our analysis did not convincingly demonstrate a higher rate of SM due to EF-RT rather than



**Figure 1.** Forest plot and Peto curves of overall second malignancy risk for the comparison radiotherapy alone versus combined chemoradiotherapy. Copyright Cochrane Library [31], reproduced with permission.

IF-RT, with the exception of breast cancers (OR 3.25 observed). An analysis censored at progression/relapse indicated a higher SM rate with EF (borderline significance), which may have been offset in the overall analysis by the significantly higher rate of progression/relapse [31], and therefore salvage therapy, after first-line IF.


### limitations of included studies

The large majority of studies used adequate methods of randomisation resulting in treatment cohorts well balanced with respect to patient characteristics. In many studies, certain randomised patients were excluded from the trialists' own analyses, against our intention-to-treat principle. We could not always reinstate such patients in our analysis: either they were omitted from the dataset or outcome data were missing.

Twelve of 37 trials had a median follow-up of at least 20 years (Tables 1–4). Several of the largest trials, however, had a median

follow-up of between 4 and 6 years, too short for detection of ST in particular. Loss to follow-up resulted in a dispersion of dates of last information in most trials (the largest interquartile range was nearly 10 years). This is a potential source of bias in estimating event rates. We, however, found no evidence of differences in follow-up pattern between the treatment arms in any trial, so a bias in treatment effect is not suggested.

The greatest source of uncertainty, in our opinion, is the reliability of reporting of SM. Particularly, the earlier trials were not designed to provide information on SM risk; underreporting is likely. Most trialists assessed their SM information as 'probably incomplete.' Few had cross-checked with death or cancer registries. Comparison of observed SM rates with those expected on the basis of cancer registry data implied serious underreporting in a few trials. On the other hand, SM rates may be overreported in the sense that patients without an event are more likely to be lost to follow-up. A bias in the estimation of treatment effect would result only if such



**Figure 2.** Forest plot and Peto curves of overall second malignancy risk for the comparison chemotherapy alone versus combined chemoradiotherapy. Copyright Cochrane Library [31], reproduced with permission.

reporting biases differed between treatment arms. Furthermore, some trialists did not record NMSC.

### meta-analysis methods

In order to obtain adequate numbers of SM events for reliable comparisons, we included trials spanning four decades with varying diagnostic and therapeutic methods. Treatment differences may vary widely according to chemotherapy regimen and radiotherapy technique. Irradiation techniques have advanced considerably since the 1960s and this may have reduced SM risk. The use of new chemotherapy drugs, avoiding alkylating agents and favouring anthracycline-containing combinations have been shown to reduce the risk of second AL [105]. Subgroup analyses generally lack power to elucidate these variations reliably. Development of more effective salvage treatment strategies will also have altered survival rates and SM risk after first-line treatment failure.



It was decided in advance to count all SM as events, including NMSC which were not counted in some previous investigations

of SM after HL. Some contributing trialists did not submit data on NMSC. We, however, performed sensitivity analyses not counting NMSC as events, which led to ORs closely consistent with the main analysis.

Although each type of SM (AL, NHL and ST), as well as lung and breast cancers, was analysed separately, total SM was the main outcome measure, since the larger number of events thus available permitted a more powerful analysis. One must, however, be aware that the counted events differ in severity.

In the present analysis, early (stages I–II) and advanced (stages III–IV) disease were analysed both together and separately. The comparisons RT versus CRT and IF-RT versus EF-RT were based largely on early-stage patients, while the majority of patients in the CT versus CRT comparison had advanced-stage disease. For reasons of statistical power, we defined the combined analysis as the main one. Heterogeneity between stages in the comparison of overall second malignancy risk, however, is likely because both (i) the treatment intensity of each modality and (ii) the progression/relapse rate and thus the frequency of salvage treatment are stage dependent. For this

Review: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk  
 Comparison: 01 RT vs. CT  
 Outcome: 21 second malignancy free survival



**Figure 3.** Forest plot and Peto curves of overall second malignancy risk for the comparison radiotherapy alone versus chemotherapy alone. Copyright Cochrane Library [31], reproduced with permission.

reason, firm conclusions for a particular comparison have been drawn only for those stages where the data for this comparison are adequate.

We found no evidence of differences in treatment comparison of SM risk according to age or sex, but again, subgroup analyses are underpowered and might miss real differences. No data were available on many potential SM risk factors, such as smoking habits.

### previous evidence

The meta-analysis by Loeffler et al. [104] reported significantly more deaths due to second AL with CRT compared with CT alone in predominantly advanced-stage patients (hazard ratio 2.48,  $P = 0.038$ ). In the present analysis, concordant results were obtained (OR = 1.82,  $P = 0.07$ ; censoring at progression/relapse: OR = 2.57,  $P = 0.02$ ). The meta-analysis by Specht et al. [77] did not detect any difference in SM-related death rates between IF-RT versus EF-RT or between RT versus CRT.

Several previous studies [5, 6, 9, 13, 21, 23] reported higher SM risk with CRT than with RT alone; none found higher risk



with RT alone as in the present review. This presumably reflects the fact that the (many) patients relapsing after RT and receiving salvage CT were classified in the CRT group in most previous studies. The report by Ng et al. [21], which classified patients according to first-line treatment only, also obtained a significantly higher relative risk of SM with initial CRT than with initial RT alone; however, this analysis included all stages IA–IVB, so patient groups with greatly differing treatment intensities were compared.

A few studies showed higher risk with CRT than with CT alone, but most found no difference. The present analysis demonstrated a higher SM rate with CRT.

Various studies have demonstrated a higher SM or AL risk with CT than with RT. The present analysis, based on an inadequate number of patients, demonstrated a non-significant trend in this direction. Two studies [21, 28] have reported a higher risk with EF-RT than with IF-RT. In the present analysis, the trend in this direction was not significant.

With two exceptions [26, 20], no significant differences between treatment modalities in the risk of ST had been previously observed, nor was a significant difference in NHL risk





**Figure 4.** Forest plot and Peto curves of overall second malignancy risk for the comparison involved-field-radiotherapy alone versus extended-field-radiotherapy alone. Copyright Cochrane Library [31], reproduced with permission.

obtained [van Leeuwen et al. [11] reported a trend ( $P = 0.06$ ) to more NHL with CRT than with either modality alone].

### implications for research

Assessment and comparison of SM risk requires reliable long-term follow-up data from large numbers of patients, ideally those enrolled in randomised trials making the relevant treatment comparisons. Although the present analysis was able to detect significant differences in SM rates, the  $P$  values obtained were not small enough to confirm these differences beyond reasonable doubt. CIs for relative SM risks are wide.

Routine follow-up documentation should include questions concerning the occurrence, type and site of second malignancies. Update campaigns should aim to fill in missing information 20–30 years after the recruitment period. Where possible, trialists should collaborate with death and cancer registries in order to record mortality and SM as completely as possible. This meta-analysis must be updated with longer

follow-up from the included studies, as well as further eligible trials, if possible restricted to currently relevant treatment regimens.

### contributors

J. Franklin was responsible for conception and planning, M. Paus and L. Specht were responsible for search for trials and contact with trialists, A. Pluetschow was responsible for data checking, A. Pluetschow and J. Franklin were responsible for data analysis and J. Franklin and A. Pluetschow constituted the writing committee.

### acknowledgements

We are grateful to the following people for advice on methods and content: K. Wheatley, S. Richards, B. Djulbegovic, R. Meyer and M. Loeffler. The Deutsche Forschungsgemeinschaft

(German Research Association) supported the project financially. This work was supported by the Competence Network Malignant Lymphomas sponsored by the German Federal Ministry of Science and Education (funding number: 01 G10491).

This paper is based on a Cochrane review first published in The Cochrane Library 2005, Issue 4 (see [www.thecochranelibrary.com](http://www.thecochranelibrary.com) for information). Cochrane reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and The Cochrane Library should be consulted for the most recent version of the review.

## references

- Henry-Amar M, Joly F. Late complications after Hodgkin's disease. *Ann Oncol* 1996; 7 (Suppl 4): 115–126.
- Henry-Amar M. Second cancer after the treatment of Hodgkin's disease: a report from the International Database on Hodgkin's Disease. *Ann Oncol* 1992; 3 (Suppl 4): 117–128.
- Tucker MA, Coleman CN, Cox RS et al. Risk of second cancers after treatment for Hodgkin's disease. *New Engl J Med* 1988; 318: 76–81.
- Pedersen-Bjergaard J, Specht L, Larsen SO et al. Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. *Lancet* 1987; 2 (8550): 83–88.
- Swerdlow AJ, Douglas AJ, Vaughan Hudson G et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. *Brit Med J* 1992; 304: 1137–1143.
- Abrahamsen JF, Andersen A, Hannisdal E et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time and age. *J Clin Oncol* 1993; 11 (2): 255–261.
- Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. *J Natl Cancer Inst* 1993; 85 (1): 25–31.
- Rodriguez M, Fuller LM, Zimmerman SO et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. *Ann Oncol* 1993; 4 (2): 125–131.
- Biti G, Cellai E, Magrini SM et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. *Int J Radiat Oncol Biol Phys* 1994; 29 (1): 25–31.
- Dietrich PY, Henry-Amar M, Cosset JM et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? *Blood* 1994; 84 (4): 1209–1215.
- van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. *J Clin Oncol* 1994; 12: 312–325.
- Bhatia S, Robison L, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. *New Engl J Med* 1996; 334 (12): 745–751.
- Mauch PM, Kalish LA, Marcus KC et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. *Blood* 1996; 87 (9): 3625–3632.
- Aisenberg AC, Finkelstein DM, Doppke KP et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. *Cancer* 1997; 79 (6): 1203–1210.
- Birdwell SH, Hancock SL, Varghese A et al. Gastrointestinal cancer after treatment of Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1997; 37 (1): 67–73.
- Enrici RM, Anselmo AP, Iacari V et al. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment. *Haematologica* 1998; 83 (7): 636–644.
- Metayer C, Lynch CF, Clarke EA et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. *J Clin Oncol* 2000; 18 (12): 2435–2443.
- Swerdlow AJ, Barber JA, Vaughan Hudson G et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort. The relation to age at treatment. *J Clin Oncol* 2000; 18: 498–509.
- van Leeuwen FE, Klokman WJ, van't Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. *J Clin Oncol* 2000; 18: 487–497.
- Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. *J Clin Oncol* 2002; 20: 3484–3494.
- Ng AK, Bernardo MVP, Weller E et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. *Blood* 2002; 100: 1989–1996.
- Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2003; 21: 3440–3446.
- Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. *New Engl J Med* 1990; 322: 7–13.
- Kaldor JM, Day NE, Bell J et al. Lung cancer following Hodgkin's disease: a case-control study. *Int J Cancer* 1992; 52: 677–681.
- van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. *J Clin Oncol* 1994; 12: 1063–1073.
- Boivin JF, Hutchison GB, Zauberg AG et al. Incidence of second cancers in patients treated for Hodgkin's disease. *J Natl Cancer Inst* 1995; 87: 732–741.
- van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. *J Natl Cancer Inst* 1995; 87: 1530–1537.
- Brusamolino E, Anselmo AP, Klersy C et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. *Haematologica* 1998; 83: 812–823.
- Swerdlow AJ, Schoemaker MJ, Allerton R et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. *J Clin Oncol* 2001; 19: 1610–1618.
- Boivin J-F, O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. *Cancer* 1988; 61: 2541–2546.
- Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk (Cochrane review). The Cochrane Library, Issue 4. Chichester, UK: John Wiley 2005.
- Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials* 1996; 17: 343–346.
- Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. *New Engl J Med* 1988; 319: 1681–1692.
- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. *Lancet* 1992; 339: 1–15, 71–85.
- Cox DR. Regression models and life tables. *J R Statist Soc B* 1972; 34: 187–220.
- Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? *Stat Med* 1993; 12: 737–751.
- Tai BC, Machin D, White I, Gebiski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. *Stat Med* 2001; 20: 661–684.
- Hoogstraten B, Glidewell O, Holland JF et al. Long term follow-up of combination chemotherapy-radiotherapy of stage III Hodgkin's disease. *Cancer* 1979; 43: 1234–1244.
- Bloomfield CD, Pajak TF, Glicksman AS et al. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. *Cancer Treat Rep* 1982; 4: 835–846.
- Aleman BMP, Raemaekers JMM, Tirelli U et al. Involved-field radiotherapy advanced Hodgkin's lymphoma. *New Engl J Med* 2003; 348: 2396–2406.

41. Carde P, Hayat M, Cosset JM et al. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer. *NCI Monogr* 1988; 6: 303–310.
42. Carde P, Noordijk EM, Hagenbeek A et al. Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I–II Hodgkin's disease: the EORTC-GPMC H7F randomized trial. *Proc Am Soc Clin Oncol* 1997; 16: 13a.
43. Hagenbeek A, Eghbali H, Ferme C et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I–II Hodgkin's disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. *Blood* 2000; 96: 575a (Abstr 2472).
44. Ferme C, Eghbali H, Hagenbeek A et al. MOPP/ABV (M/A) hybrid and irradiation in unfavorable supradiaphragmatic clinical stages (CS) I–II Hodgkin's disease (HD): comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. *Blood* 2000; 96: 576a (Abstr 2473).
45. Pavlovsky S, Santarelli MT, Muriel FS et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III–IV A & B Hodgkin's disease. *Ann Oncol* 1992; 3: 533–537.
46. Pavlovsky S, Maschio M, Santarelli MT et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin's disease. *J Natl Cancer Inst* 1988; 80: 1466–1473.
47. Ferme C, Sebban C, Hennequin C et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial. *Blood* 2000; 95: 2246–2252.
48. Diehl V, Loeffler M, Pfreundschuh M et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. German Hodgkins' Study Group (GHSG). *Ann Oncol* 1995; 6: 901–910.
49. Sieber M, Franklin J, Tesch H et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 [abstract]. *Blood* 2002; 100: 341.
50. Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2003; 21 (19): 3601–3608.
51. Zittoun R, Audebert A, Hoerni B et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. *J Clin Oncol* 1985; 3 (2): 207–214.
52. Nordentoft AM. [Radiotherapy in 50 cases of Hodgkin's disease in stages I and II. Report from the Lymphogranulomatosis Committee (LYGRA).] *Ugeskr Laeger* 1972; 134: 2382–2385.
53. Nissen NI, Nordentoft AM. Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. *Cancer Treat Rep* 1982; 66: 799–803.
54. Anderson H, Crowther D, Deakin DP et al. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA–IIB Hodgkin's disease: 10-year follow-up. *Ann Oncol* 1991; 2 (Suppl 2): 49–54.
55. Crowther D, Wagstaff J, Deakin D et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. *J Clin Oncol* 1984; 2 (8): 892–897.
56. Radford JA, Cowan RA, Ryder WDJ et al. Four weeks of VAPEC-B chemotherapy before involved field radiotherapy minimises the relapse rate in early stage, low risk Hodgkin's disease and is not associated with an excess of second malignancy. *Ann Oncol* 2002; 13 (Suppl 2): 25 (Abstr 070).
57. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. *Clin Lab Haematol* 1998; 20 (2): 95–99.
58. Bonfante V, Viviani S, Devizzi L et al. Ten-years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs. involved field (IF-RT) in early-stage Hodgkin's disease (Hd). *Proc Am Soc Clin Oncol* 2001; 20: 281a (Abstr 1120).
59. Hirsch A, Vander Els N, Straus DJ et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. *J Clin Oncol* 1996; 14 (4): 1297–1305.
60. Straus DJ, Yahalom J, Zelenetz A et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non-bulky Hodgkin's disease. *Blood* 2001; 98: 769a (Abstr 3201).
61. Yelle L, Bergsagel D, Basco V et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. *J Clin Oncol* 1991; 9: 1983–1993.
62. Baisogolov GD, Isaev IG, Pavlov VV. [Late results of drug and combined (chemo- and radiation) therapy of patients with stages IIIB–IV of lymphogranulomatosis.] *Med Radiol (Mosc)* 1980; 1: 32–36.
63. Baysogolov GD, Shakhtarina SV. The efficiency of different combined treatment programs (combination chemotherapy-radiotherapy) used for stage I–II Hodgkin's disease. *Radiother Oncol* 1987; 8 (2): 113–122.
64. Biti GP, Cimino G, Cartoni C et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. *J Clin Oncol* 1992; 10: 378–382.
65. Anselmo AP, Cantonetti M, Proia S et al. Involved-field radiotherapy (I.F.) vs extended-field radiotherapy (E.F.) after ABVD chemotherapy in intermediate stage Hodgkin's disease (HD): preliminary results. *Ann Oncol* 1996; 7 (Suppl 3): 12 (Abstr 411).
66. Anselmo AP, Bove M, Cartoni C et al. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement. *Haematologica* 1992; 77: 177–179.
67. Thompson E, Smith K, Wilimas J, Kumar M. Radiation, chemotherapy, or both in childhood and adolescent Hodgkin's disease (HD). *Proc Am Assoc Cancer Res* 1977; 18 (221) (Abstr 881).
68. Horning SJ, Hoppe RT, Mason J et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. *J Clin Oncol* 1997; 15: 1736–1744.
69. Hoppe RT, Horning SJ, Hancock SL, Rosenberg SA. Current Stanford clinical trials for Hodgkin's disease. *Recent Results Cancer Res* 1989; 117: 182–190.
70. Hoppe RT, Horning SJ, Rosenberg SA. The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. *Cancer Surv* 1985; 4: 459–475.
71. Kaplan HS, Rosenberg SA, Bissinger PA. Current status of clinical trials: Stanford experience, 1962–1972. *Natl Cancer Inst Monogr* 1973; 36: 363–371.
72. Haybittle JL, Hayhoe FG, Easterling MJ et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. *Lancet* 1985; 1: 967–972.
73. Hutchison GB. Radiotherapy of stage I and II Hodgkin's disease. A collaborative study. *Cancer* 1984; 54: 1928–1942.
74. Hutchinson RJ, Fryer CJ, Davis PC et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. *J Clin Oncol* 1998; 16: 897–906.
75. Nachman JB, Sposto R, Herzog P et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. *J Clin Oncol* 2002; 20: 3765–3771.
76. Desser RK, Golomb HM, Ultmann JE et al. Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations. *Blood* 1977; 49: 883–893.
77. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients.

- International Hodgkin's Disease Collaborative Group. *J Clin Oncol* 1998; 16: 830–843.
78. Glick JH, Tsiatis A. MOPP/ABVD chemotherapy for advanced Hodgkin's disease. *Ann Intern Med* 1986; 104: 876–878.
  79. Glick JH, Barnes JM, Bakemeier RF et al. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology Group. *Cancer Treat Rep* 1982; 66: 855–870.
  80. Glick J, Tsiatis A, Chen M et al. Improved survival with MOPP-ABVD compared to BCVP +/– radiotherapy (RT) for advanced Hodgkin's disease (HD): 6-year ECOG results. *Blood* 1990; 76 (10 Suppl 1): 351a (Abstr 1392).
  81. Andrieu JM, Coscas Y, Cramer P et al. Chemotherapy plus radiotherapy in clinical stage IA to IIIB Hodgkin's disease. Results of the H 77 trial (1977–1980). In Cavalli F, Bonadonna G, Rosenzweig M (eds): *Experimental and Therapeutic Advances*. Boston, MA: Martinus Nijhoff 1985; 353–361.
  82. Andrieu JM, Ozanne F, Dana M et al. [Multiple chemotherapy (MOPP) followed by either focal or selective radiotherapy in clinical stages IA and II2A of Hodgkin's disease: results after four years of the use of prospective schedule (H7701) in 79 patients.] *Bull Cancer* 1991; 68: 217–223.
  83. Boiron M, Teillet F, Weisgerber C et al. [Treatment of Hodgkin's disease. Our experience in Hospital Saint-Louis (Paris).] *Rev Prat* 1974; 24: 3971–3978.
  84. Gehan EA, Sullivan MP, Fuller LM et al. The Intergroup Hodgkin's disease in children. A study of stages I and II. *Cancer* 1990; 65: 1429–1437.
  85. Nordentoft AM, Pedersen-Bjergaard J, Brincker H et al. Hodgkin's disease in Denmark: a national clinical study by the Danish Hodgkin study group, LYGRA. *Scand J Haematol* 1980; 24: 321–334.
  86. Assouline D, Adeleine P, Jaubert J et al. Advanced stages Hodgkin's disease (HD): long term results of the LMS 80 protocol. *Proc Am Soc Clin Oncol* 1993; 12: 381.
  87. Aviles A, Delgado S, Talavera A et al. Adjuvant radiotherapy to initial bulky disease in patients with advanced stage Hodgkin's disease. *Hematology* 2000; 4: 479–485.
  88. Blokhina NG, Aliev BM, Kruglova GV et al. [Treatment of patients with lymphogranulomatosis, stages I and II (preliminary results of a randomized study—radiation and complex therapy).] *Vestn Akad Med Nauk SSSR* 1985; (1): 45–49.
  89. O'Dwyer PJ, Wiernik PH, Stewart MB, Slawson RG. Treatment of early stage Hodgkin's disease: a randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone. In Cavalli F, Bonadonna G, Rosenzweig M (eds): *Proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland, June 13–16, 1984, Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, VI. 6*. Boston, MA: Martinus Nijhoff Publishing 1985; 329–336.
  90. Wiernik PH, Gustafson J, Schimpff SC, Diggs C. Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results eight years later. *Am J Med* 1979; 67: 183–198.
  91. O'Connell MJ, Wiernik PH, Brace KC et al. A combined modality approach to the treatment of Hodgkin's disease. Preliminary results of a prospectively randomized clinical trial. *Cancer* 1975; 35: 1055–1065.
  92. Dutcher JP, Wiernik P. Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results 14 years later. In Cavalli F, Bonadonna G, Rosenzweig M (eds): *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*. Boston, MA: Martinus Nijhoff Pub. 1985; 317–328.
  93. Longo DL, Glatstein E, Duffey PL et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. *J Clin Oncol* 1991; 9: 906–917.
  94. Leventhal BG. The Pediatric Oncology Group. Studies in Hodgkin's disease. *Cancer Treat Res* 1989; 41: 257–262.
  95. Kung FH, Behm FG, Cantor AB et al. Abbreviated chemotherapy vs. chemoradiotherapy in early stage Hodgkin's disease of childhood. *Ann Oncol* 1996; 7 Suppl. 3: 5 (Abstr 011).
  96. Weiner MA, Leventhal B, Brecher ML et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in Hodgkin's disease in pediatric patients: a Pediatric Oncology Group Study. *J Clin Oncol* 1997; 15: 2769–2779.
  97. Gomez GA, Panahon AM, Stutzman L et al. Large mediastinal mass in Hodgkin's disease. Results of two treatment modalities. *Am J Clin Oncol* 1984; 1: 65–73.
  98. Timothy AR, Sutcliffe SB, Lister TA et al. The management of stage IIIA Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1980; 6: 135–142.
  99. Lister TA, Dorreen MS, Faux M et al. The treatment of stage IIIA Hodgkin's disease. *J Clin Oncol* 1983; 1: 745–749.
  100. Jones SE, Coltman CA Jr, Grozea PN et al. Conclusions from clinical trials of the Southwest Oncology Group. *Cancer Treat Rep* 1982; 66: 847–853.
  101. Grozea PN, Depersio EJ, Coltman CA Jr et al. Chemotherapy alone versus combined modality therapy for stage III Hodgkin's disease: a five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA. *Dev Oncol* 1985; 32: 345–351.
  102. Fabian CJ, Mansfield CM, Dahlberg S et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. *Ann Intern Med* 1994; 120: 903–912.
  103. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol* 2001; 19: 4238–4244.
  104. Loeffler M, Brosteanu O, Hasenclever D et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. *J Clin Oncol* 1998; 16: 818–829.
  105. Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin's disease. *Hematol Oncol Clin North Am* 1993; 7 (2): 369–387.